Get the Stockscreener App
4.4828
7.57%
-0.3672
Myriad Genetics Inc stock is traded at $4.4828, with a volume of 400.32K.
It is down -7.57% in the last 24 hours and down -31.77% over the past month.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
See More
Previous Close:
$4.85
Open:
$4.84
24h Volume:
400.32K
Relative Volume:
0.41
Market Cap:
$418.06M
Revenue:
$823.60M
Net Income/Loss:
$-116.00M
P/E Ratio:
-3.4483
EPS:
-1.3
Net Cash Flow:
$-107.30M
1W Performance:
-12.10%
1M Performance:
-31.77%
6M Performance:
-25.66%
1Y Performance:
-65.75%
1-Day Range:
$4.46
$4.935
1-Week Range:
$4.46
$5.29
52-Week Range:
$3.76
$15.47
Myriad Genetics Inc Stock (MYGN) Company Profile
Name
Myriad Genetics Inc
Sector
Industry
Phone
801-584-3600
Address
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
4.485 | 452.09M | 823.60M | -116.00M | -107.30M | -1.30 |
|
TMO
Thermo Fisher Scientific Inc
|
500.25 | 198.06B | 44.56B | 6.73B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
210.26 | 155.50B | 24.57B | 3.60B | 5.25B | 5.0475 |
|
IDXX
Idexx Laboratories Inc
|
633.65 | 51.80B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
121.62 | 36.46B | 6.95B | 1.30B | 1.15B | 4.5696 |
|
WAT
Waters Corp
|
309.88 | 32.29B | 3.11B | 648.81M | 602.27M | 10.88 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-21-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| May-08-25 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| May-07-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-25 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-12-25 | Initiated | Craig Hallum | Buy |
| Dec-10-24 | Initiated | UBS | Neutral |
| Dec-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-19-24 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-28-24 | Initiated | Wells Fargo | Overweight |
| Jun-27-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-03-24 | Resumed | Jefferies | Underperform |
| May-08-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-21-23 | Resumed | Piper Sandler | Neutral |
| Dec-19-23 | Initiated | Wells Fargo | Equal Weight |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Underweight |
| May-23-23 | Upgrade | Goldman | Sell → Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Oct-06-22 | Initiated | Stephens | Equal-Weight |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| Jun-03-21 | Initiated | Goldman | Sell |
| Sep-26-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Aug-14-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-02-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Aug-01-19 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-19 | Downgrade | Needham | Strong Buy → Hold |
| Jul-09-19 | Downgrade | Cowen | Outperform → Market Perform |
| Mar-12-19 | Reiterated | Needham | Strong Buy |
| Jan-03-19 | Initiated | Needham | Strong Buy |
| Nov-30-18 | Upgrade | Goldman | Sell → Neutral |
| Oct-10-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-11-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-21-18 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Jan-29-18 | Initiated | Goldman | Sell |
| Jan-22-18 | Reiterated | Barclays | Equal Weight |
| Jan-05-18 | Initiated | BTIG Research | Buy |
| Oct-02-17 | Resumed | Leerink Partners | Mkt Perform |
| Aug-09-17 | Reiterated | Barclays | Equal Weight |
| Feb-08-17 | Upgrade | Ladenburg Thalmann | Sell → Neutral |
| Jan-18-17 | Initiated | Deutsche Bank | Sell |
| Oct-10-16 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
View All
Myriad Genetics Inc Stock (MYGN) Latest News
Myriad Genetics showcases prenatal screening breakthroughs at major conference - Traders Union
Minimal Residual Disease Testing Market Poised for Rapid Growth - openPR.com
Can Myriad Genetics Inc scale operations efficientlyJuly 2025 PostEarnings & Intraday High Probability Setup Alerts - baoquankhu1.vn
Why Analysts See The Myriad Genetics (MYGN) Story Shifting After The New $7 Target - Yahoo Finance
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet? - simplywall.st
Responsive Playbooks and the MYGN Inflection - Stock Traders Daily
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Parp Inhibitor Biomarkers Market Generated Opportunities, - openPR.com
Buy Signal: Does Myriad Genetics Inc have pricing powerM&A Rumor & Weekly Momentum Picks - baoquankhu1.vn
Myriad Genetics Unveils Commercialization Roadmap For Precise MRD Assay - Nasdaq
Myriad Genetics, Inc. Advances Mrd Commercialization Timeline, Bolstered by New Study Data - marketscreener.com
Myriad Genetics (MYGN) Outlines Launch Plan for Precise MRD Assa - GuruFocus
Myriad Genetics to launch Precise MRD cancer test in March 2026 - Investing.com
Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data - The Manila Times
Myriad Genetics Announces Commercial Launch of Precise MRD™ Assay for Enhanced Cancer Detection and Monitoring - Quiver Quantitative
Myriad cancer DNA test detects signals at 1-in-a-million - stocktitan.net
Earnings Risk: Whats the outlook for Myriad Genetics Incs sectorBear Alert & Free Verified High Yield Trade Plans - baoquankhu1.vn
Understanding the Setup: (MYGN) and Scalable Risk - Stock Traders Daily
Should I hold or sell Myriad Genetics Inc. nowJuly 2025 Sector Moves & Fast Gaining Stock Reports - mfd.ru
Carrier Screening Market with Insights from Abbott - openPR.com
Myriad Genetics (NASDAQ:MYGN) Downgraded by Zacks Research to Strong Sell - MarketBeat
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm - Yahoo Finance
Myriad Genetics (NASDAQ:MYGN) Stock Price Down 6.5%Time to Sell? - MarketBeat
Momentum Shift: Does LARK stock benefit from AI growth2025 Price Momentum & Verified High Yield Trade Plans - baoquankhu1.vn
Myriad Genetics, Inc. (MYGN) Stock Analysis: Uncovering a 36.50% Potential Upside in the Diagnostics Sector - DirectorsTalk Interviews
Global Pan-Genomic and Multi-Gene Panel Testing Market Forecast to Hit US$ 25.91 Billion by 2032 at 12.04% CAGR, Driven by Growing Demand for Comprehensive Multi-Gene Diagnostics: AnalystView Market Insights - GlobeNewswire Inc.
Volume Summary: Is now the right time to enter Myriad Genetics IncMarket Sentiment Report & Fast Gaining Stock Reports - baoquankhu1.vn
What is Myriad Genetics Incs book value per share2025 Market Outlook & Daily Profit Focused Stock Screening - baoquankhu1.vn
MYRIAD GENETICS Q4 2025 Earnings Preview: Recent $MYGN Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Market Review: Can Myriad Genetics Inc. stock double in next 5 yearsOptions Play & Long-Term Safe Investment Ideas - Bộ Nội Vụ
TEM's Collab for Oncology Patient Population Is Gaining Attention - sharewise.com
The Technical Signals Behind (MYGN) That Institutions Follow - Stock Traders Daily
Myriad Genetics forecasts 2026 revenue growth of 6% to $870 million - Investing.com Canada
Myriad Genetics Reports Preliminary Q4 Revenue; Issues 2026 Guidance - Nasdaq
Myriad Genetics announces select preliminary fourth quarter and full year 2025 financial results and introduces full year 2026 financial guidance - marketscreener.com
Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance - The Manila Times
Myriad Genetics Announces Select Preliminary Fourth Quarter And Full Year 2025 Financial Results And Introduces Full Year 2026 Financial Guidance - TradingView — Track All Markets
About Us - FinancialContent
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Why Myriad Genetics Inc. stock is in analyst buy zoneJuly 2025 Institutional & Target Return Focused Stock Picks - ulpravda.ru
What Analysts Think Is Shaping The Story For Myriad Genetics (MYGN) Now - Yahoo Finance
Can Myriad Genetics Inc. stock outperform in 2025 bull market2025 Short Interest & Growth-Oriented Investment Plans - ulpravda.ru
Is Myriad Genetics Inc. (MYD) stock a good hedge against inflationJuly 2025 Highlights & Capital Protection Trading Alerts - Улправда
Will Myriad Genetics Inc. stock benefit from infrastructure spending2025 Geopolitical Influence & Verified Trade Idea Suggestions - Улправда
Can Myriad Genetics Inc. (MYD) stock surprise with quarterly resultsQuarterly Investment Review & Consistent Return Strategy Ideas - Улправда
Clinical Laboratory Services Market is expected to reach US$ - openPR.com
Myriad Genetics (NASDAQ:MYGN) Stock Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference - Sahm
Is Myriad Genetics Inc a good long term investmentMid Cap Growth Trends & Free Discover Massive Upside Stocks - earlytimes.in
The Truth About Myriad Genetics Inc: Is This DNA Stock a Sleeper Goldmine or Just Overhyped? - AD HOC NEWS
Myriad Genetics Inc Stock (MYGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
2.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):